Sanofi AEOLUS - Chronic Obstructive Pulmonary Disease (COPD) Study
Summary
The purpose of this clinical research is to look at whether dupilumab works and how safe it is in adults with Chronic Obstructive Pulmonary Disease (COPD).
If you choose and are eligible to take part, you will be in the study for a minimum of 26 weeks and up to 40 weeks.
The study will consist of 3 parts:
1. Screening Period: 3 weeks period
2. Treatment Period: 24 weeks period
3. Follow-up period: 12 weeks follow-up period
Eligibility
Eligible ages: 40 to 85
Inclusion criteria:
You might be eligible to participate in this study if:
1) You are 40 to 85 years of age,
2) You have Chronic Obstructive Pulmonary Disease (COPD).
Exclusion criteria:
You may not be eligible to participate in this study if:
1) You do not have Chronic Obstructive Pulmonary Disease (COPD).
2) Under the age of 40 or over the age of 85,
3) You are pregnant or breastfeeding.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you would like to learn more about how you can get involved with this trial, please contract our study coordinator, Madison Kong, at 403-210-7827.
Principal investigator:
Brandie Walker
Clinical trial:
Yes
REB-ID:
REB25-1198
External links